Mon-Fri 9:00-18:00 CET+39 095 7211344info@vitasanlabs.com

Family · Pharmaceutical analytical standards

Granisetron

A serotonin 5-HT3 receptor antagonist, developed by British chemists in the mid-1980s and approved in 1991: it prevents nausea and vomiting caused by chemotherapy and radiotherapy. This family brings together the active ingredient, pharmacopoeial impurities, labelled standards, nitrosamines and other impurities.

Did you know?Although it is a powerful antiemetic it does little for motion sickness: chemotherapy-induced vomiting runs through serotonin, while travel sickness follows other nerve pathways.

Granisetron HydrochlorideGo to the active ingredient →
Granisetron-d3Isotopically labelledGranisetron-d3Cat. No. P-G059-013CAS 1224925-76-1

EDQM standards 3

The official European Pharmacopoeia standards for this family.

Need a molecule you cannot find?

Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.